218 related articles for article (PubMed ID: 28722153)
1. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.
Kropeit D; Scheuenpflug J; Erb-Zohar K; Halabi A; Stobernack HP; Hulskotte EGJ; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Sep; 83(9):1944-1953. PubMed ID: 28345163
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects.
Asari K; Ishii M; Yoshitsugu H; Wakana A; Fancourt C; Yoon E; Furihata K; McCrea JB; Stoch SA; Iwamoto M
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):938-948. PubMed ID: 35238179
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
[TBL] [Abstract][Full Text] [Related]
7. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
8. Intravenous Hydroxypropyl β-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial.
Erb-Zohar K; Kropeit D; Scheuenpflug J; Stobernack HP; Hulskotte E; van Schanke A; Zimmermann H; Rübsamen-Schaeff H
Clin Transl Sci; 2017 Nov; 10(6):487-495. PubMed ID: 28675594
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
[TBL] [Abstract][Full Text] [Related]
11. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
12. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
13. Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Pérez Marín M; Decosterd LA; Andre P; Buclin T; Mercier T; Murray K; Rizzi M; Meylan P; Jaton-Ogay K; Opota O; Gengler C; Perez MH; Natterer J; Asner SA
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):96-99. PubMed ID: 31183500
[TBL] [Abstract][Full Text] [Related]
14. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S
Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
16. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
[TBL] [Abstract][Full Text] [Related]
17. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
18. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
20. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]